Recente behandelresultaten van uitgezaaid melanoom

Michiel van Zeijl; Alfons J. M. van den Eertwegh; Michel W. J. M. Wouters; Anouk Jochems; Maartje G. Schouwenburg; John B. A. G. Haanen; Maureen Aarts - Essers; Franchette W. P. J. van den Berkmortel; J. W. B. de Groot; G. A. P. Hospers; Ellen Kapiteijn; Rutger H. Koornstra; D. Piersma; R. S. van Rijn; K. P. M. Suijkerbuijk; Albert J. ten Tije; A. A. M. Van der Veldt; G. Vreugdenhil; K. J. van der Hoeven

Recente behandelresultaten van uitgezaaid melanoom

Translated title of the contribution: Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry

Michiel van Zeijl, Alfons J. M. van den Eertwegh, Michel W. J. M. Wouters, Anouk Jochems, Maartje G. Schouwenburg, John B. A. G. Haanen, Maureen Aarts - Essers, Franchette W. P. J. van den Berkmortel, J. W. B. de Groot, G. A. P. Hospers, Ellen Kapiteijn, Rutger H. Koornstra, D. Piersma, R. S. van Rijn, K. P. M. Suijkerbuijk, Albert J. ten Tije, A. A. M. Van der Veldt, G. Vreugdenhil, K. J. van der Hoeven

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVE: To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the Netherlands. DESIGN: Prospective cohort study. METHOD: We analysed data from the Dutch Melanoma Treatment Registry (DMTR) regarding patients diagnosed with unresectable stage IIIc or IV melanoma in the period of 1 July 2012 to 31 December 2015. We estimated survival times using the Kaplan-Meier method. The relationship between year of diagnosis and survival was estimated using Cox regression analysis, adjusted for age, WHO performance status, lactate dehydrogenase values, stage, brain metastases and distant metastases. RESULTS: Out of 2,768 registered patients, approximately three-quarters received systemic therapy. This treatment was subject to change every year. Median survival was 10.7 months (95% CI: 9.6-13.2) in 2012 and 13.8 months (95% CI: 11.8-15.6) in 2015. Median survival for patients receiving systemic therapy was 17.1 months in 2015. 2-year survival in this period increased from 23% to 40%. Patients diagnosed in 2015 had better survival than patients of 2014 (hazard ratio (HR) 0.82; 95% CI: 0.73-0.93). This was also true for patients receiving systemic therapy (HR: 0.79; 95% CI: 0.69-0.91). CONCLUSION: Fast availability of new drugs, initiated by the then minister of VWS (health, welfare and sport) and the professional organisation, has thoroughly changed treatment of unresectable stage IIIc and IV melanoma. Data from the DMTR indicate safe use of these new drugs in daily practice and improved survival of advanced-melanoma patients in recent years.

Translated title of the contribution	Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry
Original language	Dutch
Article number	D2420
Pages (from-to)	1-10
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	162
Publication status	Published - 15 Jun 2018

Keywords

Adult
Aged
Antineoplastic Agents/therapeutic use
Brain Neoplasms/drug therapy mortality pathology secondary
Female
Humans
Kaplan-Meier Estimate
Male
Melanoma/drug therapy mortality pathology
Middle Aged
Neoplasm Staging
Netherlands/epidemiology
Prospective Studies
Registries/statistics & numerical data
Skin Neoplasms/drug therapy mortality pathology
Treatment Outcome

Access to Document

https://www.ntvg.nl/system/files/publications/d2420.pdf

Cite this

van Zeijl, M., van den Eertwegh, A. J. M., Wouters, M. W. J. M., Jochems, A., Schouwenburg, M. G., Haanen, J. B. A. G., Aarts - Essers, M., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Koornstra, R. H., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., ten Tije, A. J., Van der Veldt, A. A. M., Vreugdenhil, G., & van der Hoeven, K. J. (2018). Recente behandelresultaten van uitgezaaid melanoom. Nederlands Tijdschrift voor Geneeskunde, 162, 1-10. Article D2420. https://www.ntvg.nl/system/files/publications/d2420.pdf

@article{98ed0195711b42c49261763fc5ea8c5c,

title = "Recente behandelresultaten van uitgezaaid melanoom",

abstract = "OBJECTIVE: To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the Netherlands. DESIGN: Prospective cohort study. METHOD: We analysed data from the Dutch Melanoma Treatment Registry (DMTR) regarding patients diagnosed with unresectable stage IIIc or IV melanoma in the period of 1 July 2012 to 31 December 2015. We estimated survival times using the Kaplan-Meier method. The relationship between year of diagnosis and survival was estimated using Cox regression analysis, adjusted for age, WHO performance status, lactate dehydrogenase values, stage, brain metastases and distant metastases. RESULTS: Out of 2,768 registered patients, approximately three-quarters received systemic therapy. This treatment was subject to change every year. Median survival was 10.7 months (95% CI: 9.6-13.2) in 2012 and 13.8 months (95% CI: 11.8-15.6) in 2015. Median survival for patients receiving systemic therapy was 17.1 months in 2015. 2-year survival in this period increased from 23% to 40%. Patients diagnosed in 2015 had better survival than patients of 2014 (hazard ratio (HR) 0.82; 95% CI: 0.73-0.93). This was also true for patients receiving systemic therapy (HR: 0.79; 95% CI: 0.69-0.91). CONCLUSION: Fast availability of new drugs, initiated by the then minister of VWS (health, welfare and sport) and the professional organisation, has thoroughly changed treatment of unresectable stage IIIc and IV melanoma. Data from the DMTR indicate safe use of these new drugs in daily practice and improved survival of advanced-melanoma patients in recent years.",

keywords = "Adult, Aged, Antineoplastic Agents/therapeutic use, Brain Neoplasms/drug therapy mortality pathology secondary, Female, Humans, Kaplan-Meier Estimate, Male, Melanoma/drug therapy mortality pathology, Middle Aged, Neoplasm Staging, Netherlands/epidemiology, Prospective Studies, Registries/statistics & numerical data, Skin Neoplasms/drug therapy mortality pathology, Treatment Outcome",

author = "{van Zeijl}, Michiel and {van den Eertwegh}, {Alfons J. M.} and Wouters, {Michel W. J. M.} and Anouk Jochems and Schouwenburg, {Maartje G.} and Haanen, {John B. A. G.} and {Aarts - Essers}, Maureen and {van den Berkmortel}, {Franchette W. P. J.} and {de Groot}, {J. W. B.} and Hospers, {G. A. P.} and Ellen Kapiteijn and Koornstra, {Rutger H.} and D. Piersma and {van Rijn}, {R. S.} and Suijkerbuijk, {K. P. M.} and {ten Tije}, {Albert J.} and {Van der Veldt}, {A. A. M.} and G. Vreugdenhil and {van der Hoeven}, {K. J.}",

year = "2018",

month = jun,

day = "15",

language = "Dutch",

volume = "162",

pages = "1--10",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Bohn Stafleu van Loghum",

}

van Zeijl, M, van den Eertwegh, AJM, Wouters, MWJM, Jochems, A, Schouwenburg, MG, Haanen, JBAG, Aarts - Essers, M, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Van der Veldt, AAM, Vreugdenhil, G & van der Hoeven, KJ 2018, 'Recente behandelresultaten van uitgezaaid melanoom', Nederlands Tijdschrift voor Geneeskunde, vol. 162, D2420, pp. 1-10. <https://www.ntvg.nl/system/files/publications/d2420.pdf>

TY - JOUR

T1 - Recente behandelresultaten van uitgezaaid melanoom

AU - van Zeijl, Michiel

AU - van den Eertwegh, Alfons J. M.

AU - Wouters, Michel W. J. M.

AU - Jochems, Anouk

AU - Schouwenburg, Maartje G.

AU - Haanen, John B. A. G.

AU - Aarts - Essers, Maureen

AU - van den Berkmortel, Franchette W. P. J.

AU - de Groot, J. W. B.

AU - Hospers, G. A. P.

AU - Kapiteijn, Ellen

AU - Koornstra, Rutger H.

AU - Piersma, D.

AU - van Rijn, R. S.

AU - Suijkerbuijk, K. P. M.

AU - ten Tije, Albert J.

AU - Van der Veldt, A. A. M.

AU - Vreugdenhil, G.

AU - van der Hoeven, K. J.

PY - 2018/6/15

Y1 - 2018/6/15

N2 - OBJECTIVE: To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the Netherlands. DESIGN: Prospective cohort study. METHOD: We analysed data from the Dutch Melanoma Treatment Registry (DMTR) regarding patients diagnosed with unresectable stage IIIc or IV melanoma in the period of 1 July 2012 to 31 December 2015. We estimated survival times using the Kaplan-Meier method. The relationship between year of diagnosis and survival was estimated using Cox regression analysis, adjusted for age, WHO performance status, lactate dehydrogenase values, stage, brain metastases and distant metastases. RESULTS: Out of 2,768 registered patients, approximately three-quarters received systemic therapy. This treatment was subject to change every year. Median survival was 10.7 months (95% CI: 9.6-13.2) in 2012 and 13.8 months (95% CI: 11.8-15.6) in 2015. Median survival for patients receiving systemic therapy was 17.1 months in 2015. 2-year survival in this period increased from 23% to 40%. Patients diagnosed in 2015 had better survival than patients of 2014 (hazard ratio (HR) 0.82; 95% CI: 0.73-0.93). This was also true for patients receiving systemic therapy (HR: 0.79; 95% CI: 0.69-0.91). CONCLUSION: Fast availability of new drugs, initiated by the then minister of VWS (health, welfare and sport) and the professional organisation, has thoroughly changed treatment of unresectable stage IIIc and IV melanoma. Data from the DMTR indicate safe use of these new drugs in daily practice and improved survival of advanced-melanoma patients in recent years.

AB - OBJECTIVE: To evaluate treatment strategies and survival of patients with unresectable stage IIIc or IV melanoma since the 2012 introduction of new drugs in the Netherlands. DESIGN: Prospective cohort study. METHOD: We analysed data from the Dutch Melanoma Treatment Registry (DMTR) regarding patients diagnosed with unresectable stage IIIc or IV melanoma in the period of 1 July 2012 to 31 December 2015. We estimated survival times using the Kaplan-Meier method. The relationship between year of diagnosis and survival was estimated using Cox regression analysis, adjusted for age, WHO performance status, lactate dehydrogenase values, stage, brain metastases and distant metastases. RESULTS: Out of 2,768 registered patients, approximately three-quarters received systemic therapy. This treatment was subject to change every year. Median survival was 10.7 months (95% CI: 9.6-13.2) in 2012 and 13.8 months (95% CI: 11.8-15.6) in 2015. Median survival for patients receiving systemic therapy was 17.1 months in 2015. 2-year survival in this period increased from 23% to 40%. Patients diagnosed in 2015 had better survival than patients of 2014 (hazard ratio (HR) 0.82; 95% CI: 0.73-0.93). This was also true for patients receiving systemic therapy (HR: 0.79; 95% CI: 0.69-0.91). CONCLUSION: Fast availability of new drugs, initiated by the then minister of VWS (health, welfare and sport) and the professional organisation, has thoroughly changed treatment of unresectable stage IIIc and IV melanoma. Data from the DMTR indicate safe use of these new drugs in daily practice and improved survival of advanced-melanoma patients in recent years.

KW - Adult

KW - Aged

KW - Antineoplastic Agents/therapeutic use

KW - Brain Neoplasms/drug therapy mortality pathology secondary

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Melanoma/drug therapy mortality pathology

KW - Middle Aged

KW - Neoplasm Staging

KW - Netherlands/epidemiology

KW - Prospective Studies

KW - Registries/statistics & numerical data

KW - Skin Neoplasms/drug therapy mortality pathology

KW - Treatment Outcome

M3 - Article

SN - 0028-2162

VL - 162

SP - 1

EP - 10

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

M1 - D2420

ER -